FDA expands Anktiva for a hard-to-treat bladder cancer
Published
Given with BCG, Anktiva is now approved for adults whose high-grade papillary bladder tumors haven't responded to BCG alone. FDA calls it the first treatment specifically for this group. In an earlier study, 62% of patients had a complete response.
Source: FDA
This is a plain-language summary. Read the original source for full details.